English | Español

Bristol-Myers Squibb
Press release submission | Aug 9, 2020

BRISTOL-MYERS SQUIBB: Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma

Press release submission | Feb 16, 2020

BRISTOL-MYERS SQUIBB: Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Carol Ostrow | Dec 27, 2017

Restrictions on Opdivo combination trials for multiple myeloma treatment lifted by FDA
Carol Ostrow | Dec 27, 2017

Seattle Genetics, Bristol-Myers Squibb report Hodgkin treatment study interim results
Carol Ostrow | Dec 26, 2017

Bristol-Myers Squibb, Pfizer, others aim to raise awareness of stroke risk in atrial fibrillation patients
Robert Hadley | Nov 8, 2017

Europe agency approves expanded use of Bristol-Myers Squibb’s Opdivo to treat advanced melanoma
Carol Ostrow | Oct 14, 2017

Opdivo approved for treating certain liver cancer patients
Carol Ostrow | Oct 1, 2017

AbbVie, Bristol-Myers Squibb collaborate on anti-cancer regimen to target lung tumors

Trending
+ Technology/Innovation
Patient Daily | May 8, 2025

Medfluence attends 2025 Annual Clinical Assembly as only strategic marketing firm
+ Technology/Innovation
Patient Daily | May 7, 2025

OTO Forum 2025 highlights innovation in ENT
+ Pharmaceuticals
Patient Daily | May 8, 2025

Pacific Research Institute CEO: Hospitals are leveraging 340B's 'perverse incentives to enrich themselves'
+ Pharmaceuticals
Patient Daily | May 8, 2025

National Library of Medicine says compounded drugs like GLP-1 offer tailored alternatives to FDA-approved treatments